NervGen Pharma Corp.

https://www.nervgen.com

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company dedicated to developing first-in-class neuroreparative therapeutics. The company's mission is to enable the nervous system to repair itself following damage, aiming to transform the lives of individuals living with neurotraumatic and neurologic conditions. NervGen Pharma's corporate office is located in Vancouver, British Columbia, Canada.

The company's lead therapeutic candidate is NVG-291, a subcutaneously administered neuroreparative peptide. NVG-291 is designed to target the inhibitory chondroitin sulfate proteoglycan (CSPG)-protein tyrosine phosphatase sigma (PTPσ) pathway, thereby promoting nervous system repair. It is currently being evaluated in Phase 1b/2a clinical trials for spinal cord injury (SCI) and has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for SCI. NervGen is also advancing NVG-300, a next-generation candidate, through preclinical evaluation for conditions such as ischemic stroke, amyotrophic lateral sclerosis (ALS), and SCI.

In recent developments, NervGen Pharma successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing alignment for RESTORE, a Phase 3 registrational study of NVG-291 for chronic tetraplegia, with initiation anticipated in mid-2026. The leadership team includes Adam Rogers, MD, who was appointed President and CEO in February 2026, and Keith Vendola, MD, MBA, who became Chief Financial Officer in April 2026.

Latest updates

NervGen Appoints Seasoned CFO as Clinical Trials Accelerate

Event summary

  • NervGen Pharma appointed Keith Vendola, MD, MBA, as Chief Financial Officer, effective immediately.
  • Vendola brings over two decades of experience in biopharmaceutical finance, investment banking, and corporate strategy.
  • He previously served as CFO of Wugen and led IO Biotech through its IPO.
  • NervGen is accelerating clinical development of NVG-291, targeting initiation of the RESTORE registrational study for chronic tetraplegia.

The big picture

The appointment of a CFO with a track record of successfully navigating biopharmaceutical financing and public markets signals NervGen’s intent to aggressively pursue commercialization of NVG-291. This move comes at a pivotal moment, as the company prepares for a critical registrational trial and faces the inherent financial risks associated with late-stage clinical development. The company's valuation will be heavily influenced by the trial's outcome and Vendola's ability to manage investor expectations.

What we're watching

Financial Discipline
Vendola's experience navigating IPOs and financial transformations suggests NervGen will prioritize capital efficiency as it scales, potentially impacting R&D spending and timelines.
Clinical Execution
The success of the upcoming RESTORE registrational study will be critical; Vendola’s financial expertise will be tested by the need to secure funding and manage costs if results are delayed or unfavorable.
Market Positioning
Given Vendola’s background, NervGen may actively explore strategic partnerships or licensing deals to expand NVG-291’s potential applications beyond spinal cord injury, which could dilute equity but broaden revenue streams.

NervGen Investor Outreach Signals Ongoing Funding Push

Event summary

  • NervGen Pharma executives will participate in the H.C. Wainwright “HCW@Home” series on April 15, 2026, and the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026.
  • Adam Rogers, NervGen’s CEO, will lead the presentations, targeting both institutional and retail investors.
  • The HCW@Home event will be a fireside chat, while the Bloom Burton conference includes a formal presentation and one-on-one meetings.
  • Presentations will be webcast and archived on NervGen’s investor relations website.

The big picture

NervGen’s investor roadshow underscores the capital-intensive nature of clinical-stage biopharmaceutical development, particularly in complex areas like spinal cord injury. The company’s reliance on external funding highlights the risk inherent in its pipeline, and the upcoming presentations will be crucial in maintaining investor confidence and securing future capital. The focus on NVG-291, the first pharmacologic candidate to show functional improvement in chronic tetraplegia, positions NervGen as a potential disruptor in a market with significant unmet need, but also faces intense scrutiny.

What we're watching

Funding Needs
The increased investor outreach suggests NervGen is actively managing its cash runway, particularly given the ongoing clinical development costs associated with NVG-291 and NVG-300.
Clinical Data
The content and reception of the presentations will reveal how NervGen is framing the CONNECT SCI trial data and managing expectations for future milestones.
Regulatory Path
The FDA and EMA designations provide a framework, but the speed of approval hinges on clinical trial success and regulatory interactions, which will be closely monitored.

NervGen Aligns with FDA on Phase 3 Tetraplegia Trial, Bolstering Neurorepair Pipeline

Event summary

  • NervGen Pharma and the FDA have reached agreement on the design of RESTORE, a Phase 3 registrational study for NVG-291 in chronic tetraplegia.
  • The primary endpoint for RESTORE will be change from baseline in GRASSP Quantitative Prehension at Week 12, a functional measure of hand use.
  • Enrollment in the Phase 1b/2a CONNECT SCI study for subacute tetraplegia is concluding, with data to be unblinded.
  • The RESTORE trial is slated to begin in mid-2026, with study initiation activities already underway.
  • CONNECT SCI data showed a +3.7 point improvement in GRASSP QtP for NVG-291 versus +0.4 for placebo, exceeding the minimally important difference of 2.0 points.

The big picture

NervGen's progress represents a significant, albeit early, step toward a pharmacologic treatment for chronic tetraplegia, a condition affecting an estimated 12,000 people annually in the US alone. The FDA’s alignment on RESTORE’s design validates the CONNECT SCI data and provides a clearer path to potential approval, but the Phase 3 trial will be a critical test of NVG-291’s efficacy and safety. The broader neurorepair market is attracting increasing investment, but remains largely preclinical, making NervGen a potential early mover.

What we're watching

Clinical Execution
The success of RESTORE hinges on patient recruitment and retention across up to 60 sites, and the ability to demonstrate statistically significant and clinically meaningful improvements in GRASSP Quantitative Prehension.
Regulatory Pathway
The FDA’s alignment on endpoints could set a precedent for future SCI therapeutic approvals, but any deviations from the agreed-upon protocol could trigger further scrutiny and delay.
Commercialization
Given the limited treatment options and high unmet need for chronic tetraplegia, the commercial viability of NVG-291 will depend on demonstrating a compelling value proposition and navigating potential reimbursement challenges.

NervGen Advances SCI Treatment, Awaits FDA Update Amid Leadership Changes

Event summary

  • NervGen reported $22.1 million in cash and investments as of December 31, 2025, up from $17.3 million the prior year.
  • The company completed an End-of-Phase 2 meeting with the FDA in 1Q 2026 and anticipates a regulatory update in early 2Q 2026.
  • NervGen expects to present biomechanical gait analysis data from the CONNECT SCI study in 2Q 2026.
  • Bill Adams retired as CFO in March 2026, and an executive search is underway to replace him.
  • The company reported a net loss of $44.1 million for the year ended December 31, 2025, including $24.8 million of non-cash expenses.

The big picture

NervGen's progress in developing NVG-291 represents a significant, albeit early, step toward a pharmacologic treatment for chronic spinal cord injury, a market with substantial unmet need. The company's reliance on FDA approval and the inherent risks of clinical development remain key challenges. The ongoing leadership transition underscores the pressure to deliver on ambitious timelines and maintain investor confidence.

What we're watching

Regulatory Risk
The FDA update in early 2Q 2026 will be critical; a negative assessment could significantly impact the Phase 3 trial timeline and investor sentiment.
Execution Risk
The transition in CFO leadership introduces execution risk, particularly as the company prepares for a Phase 3 trial and potential commercialization.
Clinical Data
The upcoming biomechanical gait analysis data release will be scrutinized to validate the observed functional improvements and differentiate genuine neural recovery from compensatory movement.

NervGen Pharma Exits TSX Venture Exchange, Streamlining Nasdaq Listing

Event summary

  • NervGen Pharma voluntarily delisted from the TSX Venture Exchange, effective March 16, 2026.
  • The company’s common shares will continue to trade on Nasdaq under the ticker symbol ‘NGEN’.
  • NervGen terminated its at-the-market equity program, having issued 245 shares for net proceeds of $1,489 between January 1 and March 12, 2026.
  • The decision is framed as a strategic move to reduce costs and administrative burdens associated with a dual listing.

The big picture

NervGen’s move to a single Nasdaq listing reflects a trend among smaller biopharma companies seeking to streamline operations and reduce compliance costs as they mature. The decision signals confidence in the company’s progress toward late-stage clinical trials for NVG-291, but also highlights the financial pressures inherent in drug development, as the ATM program was terminated to reduce complexity. The move also reduces NervGen’s exposure to the TSXV, which is generally considered to have lower liquidity and investor interest than Nasdaq.

What we're watching

Execution Risk
The stated focus on clinical execution following the delisting requires close monitoring; any setbacks in the Phase 3 trial for NVG-291 could disproportionately impact the stock price now that a potential secondary listing option is removed.
Governance Dynamics
The Board’s decision to eliminate the ATM program alongside the delisting suggests a shift in capital raising strategy; future funding needs will likely require more substantial, potentially dilutive, financing rounds.
Regulatory Headwinds
While Fast Track and Orphan Drug designations offer advantages, the FDA and EMA approval pathways remain uncertain, and any delays or unexpected requests could significantly impact NervGen’s valuation.

NervGen Bolsters Leadership with Regulatory and Advocacy Veterans

Event summary

  • NervGen Pharma appointed Shamim Ruff as Chief Regulatory Affairs Officer, bringing over 30 years of regulatory experience.
  • Christine McSherry joined as SVP, Patient Advocacy and Clinical Affairs, leveraging experience in rare disease advocacy and clinical research.
  • Ruff previously held leadership roles at Stoke Therapeutics and Sarepta Therapeutics, with a focus on regulatory strategy and approvals.
  • McSherry co-founded Casimir, a clinical research organization acquired by Emmes, and remains a Director of the Jett Foundation.
  • These appointments follow NervGen's ongoing Phase 1b/2a CONNECT SCI Study and preparations for a Phase 3 trial.

The big picture

NervGen's leadership overhaul signals a heightened focus on regulatory approval and patient engagement as the company advances its lead candidate, NVG-291, for spinal cord injury. The appointments reflect a broader trend in biopharma towards incorporating patient perspectives into clinical development and prioritizing regulatory expertise to navigate complex approval pathways. The company’s success will depend on translating this strategic shift into tangible progress in clinical trials and regulatory interactions.

What we're watching

Regulatory Headwinds
Ruff's experience navigating regulatory pathways will be critical, but the FDA's evolving standards for neuroreparative therapies could present unforeseen challenges.
Execution Risk
The success of NVG-291 hinges on the ability of this new leadership team to accelerate clinical development and secure regulatory approvals within a compressed timeframe.
Patient Engagement
McSherry's focus on patient advocacy could influence trial design and endpoints, potentially impacting the commercial viability of NVG-291 if not carefully balanced with scientific rigor.

NervGen to Intensify Investor Outreach Amidst Clinical Trial Scrutiny

Event summary

  • NervGen Pharma executives, including CEO Adam Rogers, will present at the Oppenheimer Healthcare Life Sciences Conference (Feb 25-26), TD Cowen Health Care Conference (March 2-4), and Leerink Partners Global Healthcare Conference (March 8-11).
  • Presentations will be virtual (Oppenheimer) and in-person (TD Cowen, Boston, MA).
  • The company is highlighting NVG-291, a neuroreparative peptide, currently in Phase 1b/2a clinical trials for spinal cord injury.
  • NervGen has secured Fast Track designation from the FDA and Orphan Drug designation from the EMA for SCI treatment.

The big picture

NervGen's increased investor outreach signals a heightened need to manage expectations and secure funding as the company progresses through clinical trials for NVG-291. The SCI therapeutic market represents a significant unmet need, but the high failure rate in neuroregenerative therapies creates substantial risk. The company's reliance on Fast Track and Orphan Drug designations underscores the urgency to demonstrate clinical benefit and secure regulatory approval.

What we're watching

Clinical Data
The content of NervGen's presentations will be scrutinized for any new data or insights regarding NVG-291's efficacy, as investor sentiment remains highly dependent on trial outcomes.
Regulatory Pathway
How NervGen navigates the FDA and EMA approval processes, particularly given the complexities of SCI treatments, will be a key indicator of long-term commercial viability.
Financial Resources
The company’s ability to secure additional funding, especially to support a potential Phase 3 trial, will dictate the timeline for NVG-291’s advancement and overall corporate longevity.

NervGen Pharma CFO to Retire Amidst Late-Stage Development

Event summary

  • Bill Adams, NervGen Pharma's Chief Financial Officer, will retire effective March 15, 2026.
  • NervGen has engaged an executive search firm to find a replacement for Adams.
  • Adams will remain in an advisory role during the transition period.
  • Adams has held the CFO position for six years, joining the company during a critical phase of its development.

The big picture

The departure of a CFO, especially one who has been with the company for six years, always introduces a degree of uncertainty. NervGen's timing is notable, as it moves from a development-stage company to one potentially on the cusp of commercialization. The search for a successor will be crucial in navigating the complexities of late-stage clinical trials, regulatory approvals, and eventual market launch, all while maintaining investor confidence.

What we're watching

Governance Dynamics
The selection of a new CFO will be critical, particularly given NervGen's progression into late-stage clinical trials and potential FDA review, and the market will scrutinize the candidate's experience with similar-stage biopharma companies.
Financial Stability
The timing of the CFO transition coincides with the increasing capital demands of Phase 3 trials; investors will need to assess NervGen’s ability to secure funding and maintain financial stability throughout this period.
Execution Risk
The advisory role of the outgoing CFO could provide stability, but the transition itself introduces execution risk, and the market will monitor whether the company can maintain momentum in its clinical programs and regulatory interactions.

NervGen to Detail Function Improvement Data at Spinal Cord Injury Symposium

Event summary

  • NervGen Pharma will present clinical data from the Phase 1b/2a CONNECT SCI Study at Unite2Fight Paralysis’ symposium on February 15, 2026.
  • The presentation, featuring CEO Adam Rogers, will focus on durable improvements in function, independence, and quality of life observed in chronic spinal cord injury patients.
  • The symposium, held in Washington, DC, brings together scientists, clinicians, policymakers, and patient advocates.
  • NervGen’s lead candidate, NVG-291, is a subcutaneously administered peptide and has received Fast Track and Orphan Drug designations.

The big picture

NervGen's progress represents a significant, albeit early, step toward a pharmacologic treatment for spinal cord injury, a market with substantial unmet need and limited therapeutic options. The company’s focus on durable improvements in quality of life, rather than just motor function, aligns with a growing patient-centric approach in drug development. The symposium provides a crucial platform for NervGen to engage with key stakeholders and influence the evolving treatment landscape.

What we're watching

Clinical Validation
The specifics of the data presented at the symposium will be critical in assessing the clinical significance of NVG-291’s observed improvements, particularly given the chronic nature of the patient population.
Regulatory Pathway
How the FDA and EMA interpret the CONNECT SCI data will heavily influence the design and potential success of future Phase 3 trials and the overall commercial viability of NVG-291.
Competitive Landscape
The presentation’s reception within the spinal cord injury research community will reveal how NervGen’s approach stacks up against emerging therapies and alternative treatment paradigms.

NervGen Appoints Rogers as CEO Amidst Nasdaq Listing and Clinical Advancement

Event summary

  • NervGen Pharma has appointed Adam Rogers, MD, as President and CEO, effective immediately.
  • Rogers previously served as Interim CEO and Chairman of the Board, having joined the board in July 2022.
  • The appointment follows NervGen’s recent Nasdaq listing and progress on its NVG-291 therapy for spinal cord injury.
  • Rogers was previously CEO of Hemera Biosciences, which was acquired by Janssen Pharmaceuticals.
  • NervGen has granted Rogers options totaling 717,891 shares, vesting over four years.

The big picture

NervGen's leadership change coincides with a period of heightened investor interest in neuroregenerative therapies, driven by the potential for transformative treatments in spinal cord injury and related neurological conditions. The appointment of a physician-executive like Rogers signals a focus on clinical execution and regulatory navigation, crucial for a company with a complex, late-stage asset like NVG-291. The acquisition of Hemera Biosciences by Johnson & Johnson highlights the commercial value of innovative therapies in this space, creating pressure on NervGen to deliver results.

What we're watching

Execution Risk
Rogers’ success hinges on translating his prior experience in biotech leadership and clinical development into tangible progress for NervGen's pipeline, particularly with NVG-291.
Clinical Trial Progress
The ongoing Phase 1b/2a CONNECT SCI study and preparations for a Phase 3 trial will be critical indicators of NVG-291’s efficacy and NervGen’s ability to advance its lead candidate.
Governance Dynamics
The Board's confidence in Rogers’ leadership suggests a desire for accelerated growth; how this translates into strategic decisions and resource allocation warrants close observation.

NervGen Pharma Lands Nasdaq Listing Amid Clinical Trial Momentum

Event summary

  • NervGen Pharma Corp. began trading on Nasdaq (NGEN) on January 8, 2026, following approval.
  • The listing follows the release of expanded Phase 1b/2a CONNECT SCI Study data on November 24, 2025, showing durable improvements in SCI patients.
  • The company received FDA confirmation of multiple regulatory pathways for NVG-291 in September 2025.
  • NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA.

The big picture

NervGen’s Nasdaq listing represents a significant step for a company operating in the nascent neuroreparative therapeutics space, which has historically faced high development costs and regulatory hurdles. The move provides increased access to capital and visibility, but also brings heightened scrutiny as the company advances its lead candidate, NVG-291, toward potential commercialization. The success of NVG-291 will hinge on demonstrating sustained efficacy and navigating a complex regulatory landscape.

What we're watching

Regulatory Pathway
The FDA End-of-Phase 2 meeting in early 2026 will be critical in determining the approval pathway for NVG-291, and any deviations from expectations could significantly impact timelines and valuation.
Clinical Execution
The ongoing enrollment of subacute SCI patients in the Phase 1b/2a CONNECT SCI Study and the subsequent Phase 3 trial will need to proceed efficiently to maintain momentum and demonstrate continued efficacy.
Shareholder Base
The broadened shareholder base resulting from the Nasdaq listing may introduce new investment pressures and expectations regarding growth and profitability, potentially impacting NervGen’s long-term strategic decisions.
CID: 322